1. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
   Yasuhiro Tsutani et al, 2018, BMC Cancer CrossRef
2. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
   Takashi Nakano et al, 2021, Asia-Pacific Journal of Clinical Oncology CrossRef